c_Jun (dn)
- Known as:
- c_Jun (dn)
- Catalog number:
- 000045A
- Product Quantity:
- 250ul
- Category:
- -
- Supplier:
- ABM
- Gene target:
- c_Jun ()
Related products to: c_Jun (dn)
Related articles to: c_Jun (dn)
- The neutrophil-to-lymphocyte ratio (NLR) is a simple and widely available indicator of the degree and balance of the systemic inflammatory response in critically ill patients and has been shown to predict outcomes across multiple liver syndromes, including alcohol-associated hepatitis, advanced chronic liver disease/liver cirrhosis (ACLD), and acute-on-chronic liver failure (ACLF). While NLR retains prognostic power throughout the spectrum of ACLD phenotypes, its performance may vary according to the underlying etiology of ACLD. Since efforts are ongoing to identify accessible inflammatory markers for risk stratification in ACLF, NLR has gained increasing attention. The primary aim was to determine whether NLR values differ between alcoholic, viral, and other etiologies of acute decompensation (AD), with particular focus on alcoholic liver disease (ALD). Secondary aims were to assess the prognostic potential of NLR measured at admission (NLR-0) and on day 7 of hospital stay (NLR-7). - Source: PubMed
Publication date: 2026/06/30
Žilinčanová DanielaAdamcova Selcanova SvetlanaHavaj Daniel JŠulejová KarolínaKubánek NatáliaMihoková MichaelaVybostok MiroslavŽilinčan MichalZahorec RomanSkladaný LubomírJarčuška Peter - This study investigated estrogen receptor (ER) subtype-specific effects on vascular hyporeactivity in cirrhotic portal hypertension (PHT), focusing on RhoA/ROCK signaling and β-arrestin-2. - Source: PubMed
Publication date: 2026/06/30
Sun Long-CiJi Lin-HuaZhang BinWu Zhi-Yong - Since biopsy is an invasive procedure that is not suitable for routine monitoring, and hepatitis C virus (HCV) infection in children can lead to progressive liver damage, liver fibrosis, and its sequela, cirrhosis, aspartate aminotransferase (AST)-to-platelet ratio (APRI) and the fibrosis score (FIB-4) are increasingly substituting biopsy in the evaluation of liver fibrosis. APRI and FIB-4 are promising non-invasive markers for the safe and effective assessment of liver fibrosis. Thus, this study aimed to ascertain whether APRI and FIB-4 scores may be used to identify the stage of liver fibrosis among children diagnosed with HCV. - Source: PubMed
Publication date: 2026/06/10
Nagi Salma Abdel MegeedTurky Asmaa ZakyEl Gammal Shaymaa Sabry AhmedElfiky Muhammad Abdelbaeth HassanHafez Mohamed ZaeimEl-Refaey Mohamed EEmara Ashraf A EAwad Ahmad MohamedAboElenin MabroukAhmed Hesham AbdelrahmanAbdelraheem Fatma MahmoudHablas Mohamad Ghazy AttiaAwad Khaled HassaanEl-Lebedy Ismael AkmGhoneem Reda RizkAbdelmoaty Gamila Saed KhamisGhallab Shireen RashadHassan Marwa FekryAbouzouna Zeinab Sabri - Perineural invasion (PNI) is a critical feature of oral squamous cell carcinoma (OSCC), in which Schwann cells are increasingly recognized as active contributors rather than passive structures. However, the mechanisms underlying Schwann cell phenotypic remodeling in the tumor microenvironment remain incompletely understood. This study aimed to investigate whether OSCC-derived signals induce lipid peroxidation and repair-associated phenotypic remodeling in Schwann cells that promote PNI-like tumor cell behavior, and whether inhibiting lipid peroxidation can attenuate these effects. - Source: PubMed
Publication date: 2026/07/30
Long JingWang YouzhiZou MengqiJiang GangyongJiang ZhongweiPeng Wanxiao - Chronic liver diseases (CLDs) represent a growing global health challenge, driven by the increasing prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD), its progressive inflammatory-fibrotic form (metabolic dysfunction-associated steatohepatitis - MASH), as well as viral infections, alcoholic liver disease, and autoimmune and cholestatic disorders. Despite intensive research, effective pharmacological therapies capable of halting or reversing fibrosis progression - particularly in MASH - remain lacking. In recent years, incretin-based therapies, including glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and a new generation of metabolic multi-agonists, have gained breakthrough significance. These agents demonstrate potent metabolic, anti-inflammatory, and anti-steatotic effects, as well as potential antifibrotic activity, making them promising candidates for the treatment of various CLD phenotypes, including MASLD/MASH-associated fibrosis. This review synthesizes current knowledge on the mechanisms of action of these drugs, clinical trial outcomes, and their potential application as novel, targeted therapies in CLDs. - Source: PubMed
Publication date: 2026/04/23
Jędrysik MalwinaChełstowska BeataTomasiewicz KrzysztofSzymański Filip M